Laird Norton Wetherby Wealth Management LLC Decreases Stake in Haleon plc (NYSE:HLN)

Laird Norton Wetherby Wealth Management LLC reduced its stake in Haleon plc (NYSE:HLN) by 8.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 48,663 shares of the company’s stock after selling 4,259 shares during the quarter. Laird Norton Wetherby Wealth Management LLC’s holdings in Haleon were worth $464,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. JARISLOWSKY FRASER Ltd raised its position in Haleon by 8.8% during the 4th quarter. JARISLOWSKY FRASER Ltd now owns 697,108 shares of the company’s stock worth $6,650,000 after buying an additional 56,615 shares during the last quarter. Ground Swell Capital LLC acquired a new stake in Haleon in the 4th quarter valued at $151,000. Focus Partners Wealth boosted its stake in Haleon by 132.0% during the 4th quarter. Focus Partners Wealth now owns 67,928 shares of the company’s stock worth $686,000 after purchasing an additional 38,651 shares during the last quarter. Fiduciary Trust Co boosted its stake in Haleon by 13.3% during the 4th quarter. Fiduciary Trust Co now owns 47,519 shares of the company’s stock worth $453,000 after purchasing an additional 5,565 shares during the last quarter. Finally, Dimension Capital Management LLC boosted its stake in Haleon by 11.8% during the 4th quarter. Dimension Capital Management LLC now owns 16,010 shares of the company’s stock worth $153,000 after purchasing an additional 1,689 shares during the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Performance

Shares of HLN opened at $10.66 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The firm has a market cap of $48.06 billion, a PE ratio of 31.35, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. The company’s 50 day simple moving average is $10.21 and its 200-day simple moving average is $9.86. Haleon plc has a 12-month low of $8.25 and a 12-month high of $10.85.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. As a group, equities analysts predict that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The firm also recently announced a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a $0.1166 dividend. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. This is an increase from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is 58.97%.

Analyst Ratings Changes

Several research analysts have recently weighed in on HLN shares. Morgan Stanley raised shares of Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price target on the stock in a research report on Friday, May 9th. HSBC reiterated a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Hsbc Global Res lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Finally, Barclays reiterated an “overweight” rating on shares of Haleon in a research note on Tuesday, May 6th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.25.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.